Loading organizations...
§ Private Profile · Vienna, Austria
AI-driven neurological research and therapy tablet app.
Nyra Health develops AI-powered digital therapy for neurological disorders, specializing in speech, language, and cognitive rehabilitation. Its core product, myReha, is a CE-certified application offering personalized, evidence-based therapeutic exercises. The platform also features nyra insights, an analytics and management system supporting clinics and practices in progress and aftercare.
Founded in 2020 by Dr. Philipp Schöllauf, Moritz Schöllauf, and Mario Zusag, Nyra Health originated from Dr. Philipp Schöllauf’s insights as a neurologist. Recognizing the critical need for accessible, continuous neurotherapy, he conceived a digital solution. Moritz Schöllauf brought business leadership, with Mario Zusag providing machine learning expertise.
Nyra Health serves individual patients and supports therapy practices and rehabilitation clinics. The company aims to democratize access to high-quality neurotherapy by merging advanced technology with clinical best practices. Its vision is to establish a comprehensive digital ecosystem, empowering users with effective, personalized tools for neurological recovery.
nyra health has raised $28.6M across 2 funding rounds.
nyra health has raised $28.6M in total across 2 funding rounds.
nyra health has raised $28.6M across 2 funding rounds. Most recently, it raised $23.6M Series A in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 24, 2026 | $23.6M Series A | Armira Growth | Philipp Schulte Noelle, Crane Venture Partners, EVER Pharma, Wellington Partners | Announced |
| Jun 1, 2023 | $5M Seed | MassMutual Ventures, Johannes Fischer | Albion VC, Illuminate Financial Management, Philipp Schulte Noelle | Announced |
nyra health is a Vienna-based technology company developing AI-powered digital neurotherapy solutions for patients with neurological conditions like stroke, dementia, and long COVID.[1][2][4][5] Its flagship product, the CE-certified myReha app (tablet-based), delivers personalized speech, language, and cognitive therapy through over 65,000 interactive exercises, adapting via machine learning analysis of speech patterns and biomarkers; a companion web platform, nyra.insights, tracks progress from diagnosis onward for clinics and patients.[1][2][3][6] Serving clinics, practices, patients at home (tele-rehab), and health insurers, it addresses therapy access gaps by providing scalable, evidence-based care—used by over 100 clinics, 50,000+ patients, with 98% satisfaction and 93% stronger improvements vs. standard therapy.[3][6] Recently rebranded from myReha, it raised a €4.5M oversubscribed seed round in 2024 co-led by MassMutual Ventures and Wellington Partners to expand in DACH and English-speaking markets.[2]
nyra health was founded in 2020 in Vienna, Austria, by an interdisciplinary team led by Dr. Philipp Schöllauf, a neurologist experienced in stroke rehabilitation who identified the challenge of patients losing progress post-discharge due to limited access.[1][4][5] He partnered with Mario Zusag, a machine learning researcher from Google AI and IBM Research, and Moritz Schöllauf, a lawyer specializing in regulatory affairs, collaborating with speech therapists, neuropsychologists, and ML experts to build the myReha app as a digital therapy platform.[1][5] Pivotal early traction came from over 45 hospital customers in Germany and Austria, delivering 3+ hours of weekly therapy per patient, with thousands using it for home tele-rehab; this led to the 2024 rebrand to nyra health alongside its €4.5M seed funding.[2][3]
nyra health rides the aging population-driven surge in neurological disorders (e.g., stroke, dementia), projected to rise >50% by 2050, amid resource shortages in rehab—too few staff, limited access.[2][5] Its timing aligns with AI-healthcare convergence, scaling personalized therapy where traditional methods fall short, enhanced by post-COVID telehealth momentum.[1][6] Market forces like insurer reimbursements (e.g., German DRV) and DACH expansion favor it, while influencing ecosystems via clinic integrations that boost care quality and efficiency.[2][6] As a medtech innovator, it exemplifies AI bridging evidence-based research with consumer-friendly apps, potentially accelerating global neuro-rehab standards.[1][7]
nyra health is poised for rapid scaling post-seed funding, prioritizing DACH growth, AI enhancements, and English-market entry to tap global demand.[1][2] Trends like AI biomarker tracking, tele-rehab normalization, and insurer adoption will propel it, with nyra.insights enabling data-driven advancements in dementia/long-term monitoring.[2][3] Its influence may evolve from regional leader to international player, redefining accessible neurotherapy—building on strong traction to deliver "revolutionary" patient outcomes at science's cutting edge.[1] This positions nyra health as a high-momentum bet in AI-health, directly tackling an escalating crisis with proven, scalable impact.
nyra health has raised $28.6M in total across 2 funding rounds.
nyra health's investors include Armira Growth, Philipp Schulte-Noelle, Crane Venture Partners, EVER Pharma, Wellington Partners, MassMutual Ventures, Johannes Fischer, Albion VC, Illuminate Financial Management.